

- **Name:** Byoung Chul Cho, M.D.,Ph.D
 - **Current Position & Affiliation:** 2019- Chief, Lung Cancer Center, Yonsei Cancer Center Seoul, Korea
2021- Director, Yonsei New Il Han Institute for Integrative Cancer Research Seoul, Korea
 - **Country:** Republic of Korea
-

• Educational Background:

- 1990-1995: Yonsei University College of Science Department of Biochemistry, Seoul, Korea
- 1995-1996: Exchange student (Honor student) Department of Biochemistry, Oregon State University, USA: Research on dNTP biosynthesis at Dr. C.K.Mathews Laboratory (Chairman of Department)
- 1995-2001: Yonsei University College of Medicine, Seoul, Korea
- 2000: Visiting student, Harvard Medical School (Brigham and Women's Hospital)
- 2006: Master, Department of Medicine, Yonsei University College of Medicine
- 2011: Doctor of Philosophy, Department of Medicine, Graduate School of Yonsei University (Doctoral dissertation: Apoptosis and growth inhibition by sprouty2 in non-small cell lung cancer)

• Professional Experience:

- 2001-2002: Rotating Internship, Asan Medical Center Seoul, Korea
- 2002-2006: Resident in Internal Medicine, Severance Hospital Seoul, Korea
- 2006-2008: Clinical Fellow, Yonsei Cancer Center Seoul, Korea
- 2008-2009: Instructor, Division of Medical Oncology, Yonsei Cancer Center, Seoul, Korea
- 2009-2014: Assistant professor, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine Seoul, Korea
- 2013-2015: Adjunct Senior Scientist, Cancer Science Institute Singapore
- 2014-2019: Associate professor, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine Seoul, Korea
- 2016-Present: Joint Faculty Professor, Severance Biomedical Science Institute (SBSI): 의생명과학부겸무교수 Seoul, Korea
- 2016- Present: Director, Yuhan-Yonsei lung cancer clinical and translational medicine center, Seoul, Korea
- 2019- Present: Professor, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine Seoul, Korea
- 2019- Present: Chief, Lung Cancer Center, Yonsei Cancer Center Seoul, Korea
- 2021- Present: Director, Yonsei New Il Han Institute for Integrative Cancer Research Seoul, Korea

• Professional Organizations:

- 2005-: American Society for Clinical Oncology
- 2006-: Korean Cancer Study Group (KCSG)
- 2007-: Korean Association for Clinical Oncology

- 2008-: Korean Association for the Study of Lung Cancer (Board of Publication, Journal of Lung Cancer)
- 2009-: The Korean Society for Head & Neck Oncology
- 2009-: International Association for the Study of Lung Cancer (IASLC)
- 2010-: Active member of Lung Cancer and Head & Neck Cancer Committee of KCSG

• **Main Scientific Publications:**

1. Antibody-Drug Conjugates: A New Addition to the Treatment Landscape of EGFR Mutant Non-Small Cell Lung Cancer.
Lim SM, Kim CG, Cho BC. *Cancer Res.* 2022 Jan 1;82(1):18-20. doi: 10.1158/0008-5472.CAN-21-3481.
2. Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies.
Jang SB, Kim KB, Sim S, Cho BC, Ahn MJ, Han JY, Kim SW, Lee KH, Cho EK, Haddish-Berhane N, Mehta J, Oh SW. *JTO Clin Res Rep.* 2021 Sep 8;2(10):100224. doi: 10.1016/j.jtocrr.2021.100224. eCollection 2021 Oct.
3. Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors.
Park K, Tan DSW, Su WC, Cho BC, Kim SW, Lee KH, Wang CC, Seto T, Huang DC, Jung HH, Hsu MC, Bogenrieder T, Lin CC. *JTO Clin Res Rep.* 2021 Jul 10;2(9):100206. doi: 10.1016/j.jtocrr.2021.100206. eCollection 2021 Sep.
4. Brief Report: Heterogeneity of Acquired Resistance Mechanisms to Osimertinib and Savolitinib.
Lim SM, Yang SD, Lim S, Shim HS, Cho BC. *JTO Clin Res Rep.* 2021 Apr 30;2(6):100180. doi: 10.1016/j.jtocrr.2021.100180. eCollection 2021 Jun.
5. A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Lee JH, Heo SG, Ahn BC, Hong MH, Cho BC, Lim SM, Kim HR. *Cancer Med.* 2021 Oct;10(20):7012-7020. doi: 10.1002/cam4.4231. Epub 2021 Sep 16.
6. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, Kojima T, Metges JP, Li Z, Kim SB, Cho BC, Mansoor W, Li SH, Sunpaweravong P, Maqueda MA, Goekkurt E, Hara H, Antunes L, Fountzilas C, Tsuji A, Oliden VC, Liu Q, Shah S, Bhagia P, Kato K; KEYNOTE-590 Investigators. *Lancet.* 2021 Aug 28;398(10302):759-771. doi: 10.1016/S0140-6736(21)01234-4